Table 1.

IMRAB and IMSAB A. baumannii isolates analyzed by PFGE

Isolate no.aDate of isolation (mo[s]/yr)WardbSusceptibility patterncPFGE group
CBPCAZTOB
IMRAB 1–52–4/97MICURRS/IA
IMRAB 6–233–6/97SICURRS/IA
IMRAB 245–6/97SICURRRA
IMRAB 25–274–6/97DERMRRRA
IMRAB 28–307–11/97IMEDRRRA
IMSAB-PRE 3111/96MICUSSSB
IMSAB-PRE 3212/96MUNISIRC
IMSAB-PRE 331/97MUNISISC
IMSAB-AT 342/97SUNISRSD-1
IMSAB-AT 357/97SURGSRSD-1
IMSAB-AT 367/97IMEDSRSD-2
IMSAB-AT 374/97SICUSSSE
IMSAB-PST 381/98SUNISRRF
IMSAB-PST 391/98SICUSSSG
IMSAB-PST 402/98SICUSIRH
  • a PRE, Preoutbreak; AT, At outbreak; PST, postoutbreak.

  • b MICU, medical ICU; SICU, surgical ICU; DERM, dermatology; IMED, internal medicine; SUNI, surgical unit; MUNI, medical unit.

  • c CBP, carbapenem (imipenem and meropenem); CAZ, ceftazidime; TOB, tobramycin. R, resistant; I, intermediate; S, susceptible according to NCCLS criteria.